Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Secologanin SCHEMBL431171 | 0.84 | STAT3 (0.55) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL28663748 | 0.77 | STAT3 (0.55) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL31006406 | 0.75 | STAT3 (0.55) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL2135813 | 0.75 | STAT3 (0.52) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL2135809 | 0.75 | STAT3 (0.52) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL29425864 | 0.74 | STAT3 (0.64) | STAT3MAPT | |
| SCHEMBL30004407 | 0.74 | HTR1A (0.46) | POLBCTDSP1HTR1ASTAT3MEN1 | |
| SCHEMBL29391273 | 0.73 | POLB (0.49) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL29629350 | 0.73 | POLB (0.49) | POLBCTDSP1STAT3MEN1MAPT | |
| Strictosidine SCHEMBL8322946 | 0.73 | HTR1A (0.56) | POLBCTDSP1HTR1ASTAT3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019178267-A2 | INDUCTIVE REGENERATION OF THE AIRWAY BY TRANSCRIPTIONAL FACTOR MODULATION OF GLANDULAR MYOEPITHELIAL STEM CELLS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-09-19 | — | — | WO | claimed |
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS PATHFINDER LIMITED (GB) | 2024-02-08 | — | — | US | disclosed |
| EP-4263504-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | COMPASS Pathfinder Limited (GB) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022133314-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | NEW ATLAS BIOTECHNOLOGIES, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043382-A1 | MODIFIED INDOLE ALKALOIDS FOR THERAPEUTIC USES | INMT, AANAT, HNMT | POLB 3500/4885CTDSP1 3483/4885HTR1A 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.